Robert Cyran, U.S. tech columnist, joined Breakingviews in London in 2003 and moved four years later to New York, where he continues to cover global technology, pharmaceuticals and special situations. Robert began his career at Forbes magazine, where he assisted in the startup of the international version of the magazine. Before working at Breakingviews he worked as a market researcher and reporter covering the pharmaceutical industry. Robert has a Masters degree in economics from Birmingham University and an undergraduate degree from George Washington University. Follow Rob on Twitter @rob_cyran
- Tel: +1 646 223 6083
- E-mail: email@example.com
A Beijing regulator ordered Apple to stop selling some smartphones in the city because their design was too close to a Chinese firm’s model. The ruling probably won’t have much effect, but it’s a reminder of the uneven field upon which Apple, Uber and others are playing.
The cloud storage service is now generating cash, its CEO says. Not needing to tap investors for funds is a plus, but that should be the norm for a firm worth $10 bln. As long as other startups achieve similar valuations while burning cash, there’s still too much capital around.
New therapies using the immune system may someday turn cancer into a chronic, not deadly, condition. They may also cause drug spending to triple. The next U.S. president might avoid action – but the increasing fiscal strain makes price controls or harder negotiations inevitable.
- Tech-company cash hoards come with a big asterisk
- Microsoft's CEO abandons prudence with LinkedIn
- Apple and Google face app-store squeeze
- Valeant may strain to engineer way out the in door
- Wheezing unicorns catching breath of fresh IPO air
- J&J's corpulence defense weighs heavy
- Salesforce fluffs up cloud business at a high cost